WellPoint Expands Access To Crestor Based On JUPITER Review
Executive Summary
WellPoint is removing some obstacles to coverage for AstraZeneca's Crestor (rosuvastatin) in its commercial plans in recognition of the improved cardiovascular outcomes reported in the widely publicized JUPITER study. However, the drug will continue to be classified as a tier 3 non-preferred brand
You may also be interested in...
Crestor Gets Advisory Committee For Preventing Cardiovascular Events
If AstraZeneca gets JUPITER results on label, it could improve reimbursement for the indication in patients with healthy cholesterol levels but biomarker for inflammation and at least one CVD risk factor.
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting